Short answer · Medically reviewed summary · Last updated: 2026-04-07
The primary treatment for Apert Syndrome involves a series of staged surgical procedures, beginning in infancy, to address craniosynostosis, syndactyly, and associated airway or midface challenges. Surgical and Clinical Management Because Apert Syndrome is characterized by the premature fusion of cranial sutures, the initial surgical priority is usually cranial vault remodeling, typically performed within the first year of life to allow for normal brain expansion. Following this, surgical separation of the complex syndactyly (webbed fingers and toes) is standard practice to improve hand and foot function.
The primary treatment for Apert Syndrome involves a series of staged surgical procedures, beginning in infancy, to address craniosynostosis, syndactyly, and associated airway or midface challenges.
Because Apert Syndrome is characterized by the premature fusion of cranial sutures, the initial surgical priority is usually cranial vault remodeling, typically performed within the first year of life to allow for normal brain expansion. Following this, surgical separation of the complex syndactyly (webbed fingers and toes) is standard practice to improve hand and foot function. Because Apert Syndrome often affects the midface, orthognathic surgery (jaw surgery) is frequently required during adolescence to correct malocclusion and improve respiratory function.
Effective management of Apert Syndrome requires a multidisciplinary craniofacial team. This team must include a pediatric neurosurgeon, a plastic or craniofacial surgeon, an otolaryngologist (ENT) for airway and hearing management, an orthodontist, and a speech-language pathologist. Early intervention with physical and occupational therapy is essential to maximize developmental milestones and fine motor skills as the child grows.
There are no curative medications for Apert Syndrome; however, medications may be prescribed to manage specific complications. These may include antibiotics for recurrent ear infections or, in some cases, medications to address elevated intracranial pressure. Clinical research into the fibroblast growth factor receptor 2 (FGFR2) mutation, which causes Apert Syndrome, is ongoing, focusing on understanding the molecular pathways to potentially improve long-term outcomes, though clinical trials for pharmacological interventions remain in early stages.
Treatment effectiveness varies significantly based on the severity of the skeletal fusion and the timing of interventions. Every patient’s care plan must be personalized by their medical team, as the clinical presentation of Apert Syndrome is highly variable. Regular monitoring of intracranial pressure, hearing, and dental development is vital throughout childhood and into adulthood.
Medical Disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.